Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$67.45

-0.47 (-0.69%)

07:13
03/13/18
03/13
07:13
03/13/18
07:13

Bristol-Myers, GRYT Health announce new digital pilot

GRYT Health and Bristol-Myers Squibb announced a strategic pilot utilizing de-identified data to integrate patient insights and clinical research with the goal of building a foundation of real-world data that will support improved clinical trial design, disease management and the overall well-being of patients living with cancer. The pilot will provide Bristol-Myers Squibb with valuable insights from patients on their experiences with cancer through GRYT's Stupid Cancer app, the most used patient and caregiver platform in oncology. The app is designed to instantly and anonymously connect people affected by cancer with each other, give them a platform for exchange and empower them with important resources and information. By learning more about how patients experience and manage their disease, Bristol-Myers Squibb and GRYT aim to accelerate health innovations and improve quality of life for patients.

  • 13

    Mar

BMY Bristol-Myers
$67.45

-0.47 (-0.69%)

03/12/18
LEER
03/12/18
UPGRADE
Target $66
LEER
Outperform
Leerink upgrades Merck to Outperform ahead of KN-189 presentation
Leerink analyst Seamus Fernandez upgraded Merck (MRK) to Outperform from Market Perform with an unchanged price target of $66. The shares closed Friday up 38c to $55.14. Keytruda will continue to dominate the first-line non-small cell lung cancer market, Fernandez tells investors in a research note. Following his firm's lung cancer survey, the analyst believes Merck will deliver upside to consensus Keytruda estimates along with positive earnings leverage in the second half of 2018 and 2019. He thinks KN-189 likely will show a clinically meaningful overall survival benefit for the Keytruda plus chemo combo in all patients, including a strong benefit in patients with moderate or low PD-L1 biomarker levels. Fernandez does not believe Bristol-Myers' (BMY) Opdivo and Yervoy combo will supplant Keytruda as the market leader. The analyst thinks now is the time to own shares of Merck.
03/02/18
MZHO
03/02/18
NO CHANGE
Target $89
MZHO
Buy
Mizuho has increased conviction in Bristol possibly buying Nektar in 2018
Mizuho analyst Difei Yang believes there is a possibility for Bristol-Myers Squibb (BMY) to acquire Nektar Therapeutics (NKTR) in 2018. The analyst says new positive clinical data of NKTR-214 in combo with Bristol-Myers' Opdivo reinforces her conviction. Bristol-Myers "could make a move" prior to the readouts of Propel study, expected in the second half of 2018, where NKTR-214 was tested in combo with competing products, Tecentiq and Keytruda, Yang tells investors in a research note. The analyst keeps a Buy rating on Nektar with an $89 price target following the company's Q4 results.
02/20/18
JEFF
02/20/18
INITIATION
Target $61
JEFF
Buy
Armo BioSciences initiated with a Buy at Jefferies
Jefferies analyst Biren Amin started Armo BioSciences (ARMO) with a Buy rating and $61 price target. The analyst thinks the shares will trade on potential for AM0010, an IL-10 cytokine. The data in non-small-cell lung carcinoma show "encouraging signals" and the pancreatic cancer data suggest better activity than chemo alone, Amin tells investors in a research note. He notes cytokines have recently garnered interest after Nektar Therapeutics (NKTR) inked a partnership with Bristol-Myers (BMY) for a $1.8B upfront.
02/16/18
SBSH
02/16/18
NO CHANGE
Target $78
SBSH
Buy
Three developments make Pfizer buying Bristol-Myers more likely, says Citi
Citi analyst Andrew Baum raised his price target for Bristol-Myers Squibb (BMY) to $78 from $72 saying three developments over the last week have increased the probability of a Pfizer (PFE) takeover to near 65% from 50%. Bristol closed yesterday up $3.64, or 5.6%, to $68.98. First, Bristol's revenue potential in non-small cell lung cancer is partly de-risked through Checkmate-227 tumor mutation burden data, Baum tells investors in a research note. Second, the NKTR-214 development collaboration and equity stake in Nektar Therapeutics (NKTR) could materially increase Bristol's Opdivo market share, the analyst adds. And third, he believes Pfizer's immuno-oncology efforts "are looking increasingly suspect." Bristol-Myers is likely Pfizer's last chance to have a meaningful position in the $50B-plus per annum immuno-oncology market, Baum contends. He reiterates a Buy rating on Bristol shares.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
12/14/18
12/14
12:17
12/14/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
12/14/18
12/14
12:16
12/14/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$133.26

-14.54 (-9.84%)

, SBUX

Starbucks

$64.61

-2.29 (-3.42%)

12:15
12/14/18
12/14
12:15
12/14/18
12:15
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks opened lower…

JNJ

Johnson & Johnson

$133.26

-14.54 (-9.84%)

SBUX

Starbucks

$64.61

-2.29 (-3.42%)

ADBE

Adobe

$233.37

-14.34 (-5.79%)

COST

Costco

$207.71

-18.7 (-8.26%)

BEL

Belmond

$24.67

7 (39.62%)

LVMUY

LVMH

$0.00

(0.00%)

KANG

iKang Healthcare

$20.30

2.03 (11.11%)

IDRA

Idera Pharmaceuticals

$5.34

-1.26 (-19.09%)

CDE

Coeur Mining

$3.89

-0.165 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

PFE

Pfizer

$43.45

-1.105 (-2.48%)

12:14
12/14/18
12/14
12:14
12/14/18
12:14
Hot Stocks
Pfizer announces new $10B share repurchase program »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

PFE

Pfizer

$43.52

-1.03 (-2.31%)

12:13
12/14/18
12/14
12:13
12/14/18
12:13
Hot Stocks
Pfizer raises quarterly dividend 6% to 36c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

PFE

Pfizer

$43.52

-1.03 (-2.31%)

12:12
12/14/18
12/14
12:12
12/14/18
12:12
Hot Stocks
Breaking Hot Stocks news story on Pfizer »

Pfizer boosts dividend to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

ECA

Encana

$5.93

-0.295 (-4.74%)

12:10
12/14/18
12/14
12:10
12/14/18
12:10
Options
Call buyers in Encana as shares suffer additional losses »

Call buyers in Encana as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$2.76

0.02 (0.73%)

12:08
12/14/18
12/14
12:08
12/14/18
12:08
Hot Stocks
CVI Investments reports 9.9% passive stake in Tonix Pharmaceuticals »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYH

Community Health

$3.94

-0.45 (-10.25%)

12:00
12/14/18
12/14
12:00
12/14/18
12:00
Hot Stocks
Community Health falls -10.2% »

Community Health is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$132.65

-15.15 (-10.25%)

12:00
12/14/18
12/14
12:00
12/14/18
12:00
Hot Stocks
Johnson & Johnson falls -10.3% »

Johnson & Johnson is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UGAZ

VelocityShares 3x Long Natural Gas ETN

$101.00

-17 (-14.41%)

12:00
12/14/18
12/14
12:00
12/14/18
12:00
Hot Stocks
VelocityShares 3x Long Natural Gas ETN falls -14.4% »

VelocityShares 3x Long…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIVI

Civitas Solutions

$14.68

2.05 (16.23%)

12:00
12/14/18
12/14
12:00
12/14/18
12:00
Hot Stocks
Civitas Solutions rises 14.6% »

Civitas Solutions is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

SPY

SPDR S&P 500 ETF Trust

$262.10

-3.31 (-1.25%)

12:00
12/14/18
12/14
12:00
12/14/18
12:00
Options
$10.5M sweep of SPDR 500 Trust upside calls »

$10.5M sweep of SPDR 500…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$73.25

9.63 (15.14%)

12:00
12/14/18
12/14
12:00
12/14/18
12:00
Hot Stocks
VelocityShares 3x Inv Natural Gas ETN rises 14.7% »

VelocityShares 3x Inv…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BEL

Belmond

$24.69

7.015 (39.70%)

12:00
12/14/18
12/14
12:00
12/14/18
12:00
Hot Stocks
Belmond rises 39.8% »

Belmond is up 39.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNE

Sony

$51.75

-0.45 (-0.86%)

, T

AT&T

$30.21

0.3 (1.00%)

11:56
12/14/18
12/14
11:56
12/14/18
11:56
On The Fly
Box Office Battle: 'Spider-Man: Into the Spider-Verse' swings into theaters »

Welcome to "Box Office…

SNE

Sony

$51.75

-0.45 (-0.86%)

T

AT&T

$30.21

0.3 (1.00%)

CMCSA

Comcast

$36.68

-0.07 (-0.19%)

CMCSK

Comcast

$0.00

(0.00%)

DIS

Disney

$113.21

-0.17 (-0.15%)

FOXA

21st Century Fox

$49.26

0.13 (0.26%)

FOX

21st Century Fox

$49.02

0.14 (0.29%)

LGF.A

Lionsgate

$16.00

0.25 (1.59%)

LGF.B

Lionsgate

$14.90

0.3 (2.05%)

VIA

Viacom

$31.85

0.22 (0.70%)

VIAB

Viacom

$29.28

0.41 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 30

    Jan

  • 20

    Mar

EPD

Enterprise Products

$26.15

-0.15 (-0.57%)

11:55
12/14/18
12/14
11:55
12/14/18
11:55
Options
Enterprise Products put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

NTR

Nutrien

$47.01

-0.02 (-0.04%)

11:49
12/14/18
12/14
11:49
12/14/18
11:49
Hot Stocks
Nutrien increases existing share repurchase program »

Nutrien announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNC

Lincoln National

$54.54

0.11 (0.20%)

11:48
12/14/18
12/14
11:48
12/14/18
11:48
Hot Stocks
Lincoln Financial appoints Leon Roday as General Counsel »

Lincoln Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$131.24

-16.56 (-11.20%)

11:44
12/14/18
12/14
11:44
12/14/18
11:44
Recommendations
Johnson & Johnson analyst commentary  »

J&J $40B loss in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWFT

Swift Transportation

$0.00

(0.00%)

, WERN

Werner

$30.52

-0.48 (-1.55%)

11:41
12/14/18
12/14
11:41
12/14/18
11:41
Hot Stocks
DOJ sues freight companies for systematic overcharging of shipments »

The United States has…

SWFT

Swift Transportation

$0.00

(0.00%)

WERN

Werner

$30.52

-0.48 (-1.55%)

JBHT

J.B. Hunt

$93.32

-2.57 (-2.68%)

ODFL

Old Dominion

$125.75

-0.79 (-0.62%)

KNX

Knight-Swift

$26.88

-0.44 (-1.61%)

ARCB

ArcBest

$35.22

-0.38 (-1.07%)

YRCW

YRC Worldwide

$4.13

-0.3 (-6.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$93.98

-0.37 (-0.39%)

11:40
12/14/18
12/14
11:40
12/14/18
11:40
Options
Lowes calls active »

Lowes calls active.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

JNJ

Johnson & Johnson

$132.94

-14.86 (-10.05%)

11:38
12/14/18
12/14
11:38
12/14/18
11:38
Recommendations
Johnson & Johnson analyst commentary  »

Johnson & Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTX

Leap Therapeutics

$2.92

0.07 (2.46%)

11:36
12/14/18
12/14
11:36
12/14/18
11:36
Conference/Events
Leap Therapeutics to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

11:35
12/14/18
12/14
11:35
12/14/18
11:35
General news
President Trump says 'China wants to make a big' trade deal »

President Donald Trump…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$262.91

-2.5 (-0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.